Robert R Ruffolo, PhD

Robert Ruffolo is a distinguished scientist, globally recognized for his executive leadership in the pharmaceutical industry. He served as the President of R&D and Senior Vice President of Wyeth Pharmaceuticals (now, Pfizer) from 2002 to 2008. Prior to Wyeth, Dr Ruffolo served as Senior Vice President, R&D, at SmithKline Beecham Pharmaceuticals (now, GlaxoSmithKline) for 17 years. He has played a significant role in the discovery and development of a number of successful products, including Carvedilol, Ropinirole, Dobutamine and Eprosartan. 

Dr Ruffolo has won several prestigious awards, including the Discoverer’s Award in 2008 for his pioneering work on the discovery of Carvedilol for the treatment of congestive heart failure. He has published over 500 full-length publications, edited 15 books, and was Editor-in-Chief of four international pharmacology journals. Dr Ruffolo was appointed to Aragen’s (formerly, GVK BIO) Board of Directors in April 2019. He was also a Board of Director of Aridis Pharmaceuticals Inc., USA from April 2016 to March 2023.